Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Recurrence 4Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1

Interventions

Brentuximab Vedotin 4Bexarotene 2iratumumab 1Vitamin B 12 1Salvia hispanica seed extract 1Methotrexate 1Lenalidomide 1Folic Acid 1Cholecalciferol 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Primary Cutaneous Anaplastic Large Cell × Vitamin B 12 × Lymphoid × Clear all
NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡